That said, only 14% of drugs in clinical trials make it to FDA approval, according to Research from MIT ... This update came ...

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

In September, the FDA approved the first new schizophrenia treatment in decades. 1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for ...

"Cobenfy serves as a reminder for what works ... They also need to compensate for the nine in ten drug candidates that never gain FDA approval. In some cases, a drug's journey to approval can ...

On Sept. 26, the FDA approved the first truly new antipsychotic in decades: Cobenfy. In clinical trials, it didn’t cause certain side effects that traditionally interfere with medication ...

It was licensed from Albany Molecular Research, Inc. (now Curia) and was previously developed by Bristol Myers Squibb (BMS: recently obtained FDA approval for Cobenfy, a first-in-class treatment for ...

The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride, or KarXT) on Sept. 26. Cobenfy is a capsule intended to be taken orally to treat schizophrenia in adults. It ...